Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SR-0813 is a potent and selective inhibitor of the YEATS domain in ENL/AF9. It has an IC 50 of 25 nM and EC 50 of 205 nM for the ENL YEATS domain and an IC 50 of 311 nM and EC 50 of 76 nM (CETSA) for the AF9 YEATS domain. SR-0813 exhibits over 100-fold lower affinity (Kd =3.5 μM) for MAP3K19 compared to ENL YEATS (Kd =30 nM). It can be utilized in acute leukemia research.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 932 | 现货 | ||
5 mg | ¥ 2,320 | 现货 | ||
10 mg | ¥ 3,860 | 现货 | ||
25 mg | ¥ 6,730 | 现货 | ||
50 mg | ¥ 9,130 | 现货 | ||
100 mg | ¥ 12,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,690 | 现货 |
产品描述 | SR-0813 is a potent and selective inhibitor of the YEATS domain in ENL/AF9. It has an IC 50 of 25 nM and EC 50 of 205 nM for the ENL YEATS domain and an IC 50 of 311 nM and EC 50 of 76 nM (CETSA) for the AF9 YEATS domain. SR-0813 exhibits over 100-fold lower affinity (Kd =3.5 μM) for MAP3K19 compared to ENL YEATS (Kd =30 nM). It can be utilized in acute leukemia research. |
靶点活性 | AF9 YEATS domain:311 nM (IC50), AF9 YEATS domain:76 nM (EC50), ENL YEATS domain:205 nM (EC50), ENL YEATS domain:25 nM (IC50), ENL YEATS domain:30 nM (Kd), MAP3K19:3.5 μM (Kd) |
体外活性 | SR-0813 (compound 10; 0, 1, 10 μM; 4 h) dose-dependent evicts ENL from known ENL binding sites, including the HOXA10 gene body and MYB promoter in MV4;11 cells [1] . SR-0813 (0, 1, 10 μM; 0, 24, 48, 72 h) downregulates the transcript levels of HOXA9 , MEIS1 , and MYC , and increases the abundance of the ITGAM transcript in MV4;11 cells [1] . SR-0813 (0, 1, 10 μM; approximately 2 weeks) inhibits the growth of multiple lineage leukemia (MLL)-fusion leukemia cell lines (MV4;11, MOLM-13, OCI/AML-2) and HB11;19 cells [1] . SR-0813 (1 μM, 4h) does not elicit global changes in gene expression in MV4;11 cells, but produces a strikingly selective suppression of ENL target genes [1] . Cell Proliferation Assay [1] Cell Line: MLL-fusion leukemia cell lines: MV4;11 (MLL-AF4 AML), MOLM-13 (MLL-AF9 AML), and OCI/AML-2 (MLL-AF6 AML), which are sensitive to the genetic loss of ENL. HB11;19 cells, which harboring an MLL-ENL fusion. Concentration: 0, 1, 10 μM Incubation Time: Approximately 2 weeks Result: Inhibited the growth of cells. |
分子量 | 496.62 |
分子式 | C25H32N6O3S |
CAS No. | 2597186-19-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (100.68 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0136 mL | 10.0681 mL | 20.1361 mL | 50.3403 mL |
5 mM | 0.4027 mL | 2.0136 mL | 4.0272 mL | 10.0681 mL | |
10 mM | 0.2014 mL | 1.0068 mL | 2.0136 mL | 5.034 mL | |
20 mM | 0.1007 mL | 0.5034 mL | 1.0068 mL | 2.517 mL | |
50 mM | 0.0403 mL | 0.2014 mL | 0.4027 mL | 1.0068 mL | |
100 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.5034 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SR-0813 2597186-19-9 Chromatin/Epigenetic Epigenetic Reader Domain SR 0813 SR0813 Inhibitor inhibitor inhibit